Get startedLog in
    Picture of Morphosys AG logo

    MOR — Morphosys AG News Story

    0.000.00%
    de flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMid CapMomentum Trap
    All News

    Brief: MorphoSys Presents New Long-Term Data From L-Mind Suggesting Durable Response To Treatment With Monjuvi® For Patients With R/R DLBCL

    Picture of Morphosys AG logoMorphosys AG
    28/09/2022 21:02
    Sept 28 (Reuters) - MorphoSys AG  MORG.DE :
    * MORPHOSYS PRESENTS NEW LONG-TERM DATA FROM L-MIND
SUGGESTING
DURABLE RESPONSE TO TREATMENT WITH MONJUVI® (TAFASITAMAB-CXIX)
FOR PATIENTS WITH R/R DLBCL
    * MORPHOSYS US - COMPLETE RESPONSE WAS OBSERVED IN 23 OF 27
PATIENTS, INCLUDING FOUR WHO WERE REFRACTORY TO THEIR PRIMARY
THERAPY IN STUDY

Source text for Eikon:  ID:nBw4fnrGxa 
Further company coverage:  MORG.DE

    Recent news on Morphosys AG

    See all news